Cotización Recordati - REC

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Último Precio

48.36

Postura de Compra

47.62

Postura de Venta

48.50

Volume Operado de la Acción

251,518

47.78 Rango del Día 48.44

46.34 Rango de 52 semanas 60.50

Capitalización de Mercado [m]

9.931B

Precio Anterior

48.50

Precio de Apertura

48.18

Hora

370

48.36

Última hora de negociación

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

452,042

Acciones en circulación

205,358,104

Rendimiento del Dividendo

2.48%

Ratio Precio/Utilidad

25.85

Beneficio por acción (BPA)

1.9

turnover

2.07B

Beneficio neto

389.21M

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

www.recordati.it

Sede

Milan, Lombardy, Ita

Fundado

1926

Recordati SpA is listed in the Pharmaceutical Preparations sector of the Italian Stock Exchange with ticker REC. The last closing price for Recordati was 48.50 €. Over the last year, Recordati shares have traded in a share price range of 46.34 € to 60.50 €.

Recordati currently has 205,358,104 shares in issue. The market capitalisation of Recordati is 9.96 € billion. Recordati has a price to earnings ratio (PE ratio) of 25.85.

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S...

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED...

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5...

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE Milan, 4th October 2024 –...

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease

The LINC 4 study demonstrated superiority of Isturisa® (osilodrostat) over placebo in achieving cortisol normalisation during the 12-week...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0.56	1.17154811715	47.8	48.5	47.12	317633	48.15224466	DE
4	-4.99	-9.35332708529	53.35	54.3	46.34	428480	50.76646215	DE
12	-7.39	-13.2556053812	55.75	60.5	46.34	452042	54.21756046	DE
26	-5.34	-9.94413407821	53.7	60.5	46.34	352409	53.35085973	DE
52	-0.76	-1.54723127036	49.12	60.5	46.34	296785	52.07407582	DE
156	0.55	1.15038694834	47.81	60.5	34.52	249630	46.73260299	DE
260	10.19	26.6963583966	38.17	60.5	34.52	273661	46.64274569	DE

REC - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Recordati?

El precio actual de las acciones de Recordati es 48.36 €

¿Cuántas acciones de Recordati están en circulación?

Recordati tiene 205,358,104 acciones en circulación

¿Cuál es la capitalización de mercado de Recordati?

La capitalización de mercado de Recordati es EUR 9.96B

¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Recordati?

Recordati ha negociado en un rango de 46.34 € a 60.50 € durante el último año

¿Cuál es el ratio PE (precio/beneficio) de Recordati?

El ratio precio/beneficio de Recordati es 25.85

¿Cuál es el ratio de efectivo a ventas de Recordati?

El ratio de efectivo a ventas de Recordati es 4.87

¿Cuál es la moneda de reporte de Recordati?

Recordati presenta sus resultados financieros en EUR

¿Cuál es el último ingresos anual de Recordati?

El último ingresos anual de Recordati es EUR 2.07B

¿Cuál es el último beneficio anual de Recordati?

El último beneficio anual de Recordati es EUR 389.21M

¿Cuál es la dirección registrada de Recordati?

La dirección registrada de Recordati es VIA MATTEO CIVITALI 1, MILAN, LOMBARDY, 20148

¿Cuál es la dirección del sitio web de Recordati?

La dirección del sitio web de Recordati es www.recordati.it

¿En qué sector industrial opera Recordati?

Recordati opera en el sector PHARMACEUTICAL PREPARATIONS

Símbolo	Precio	Vol.
1SPCEVirgin Galactic Holdings Inc	3.074 € (19.15%)	924
TDTrenDevice Spa	0.127 € (15.45%)	261k
1LLYLilly Eli and Co	733.60 € (11.46%)	2.05k
1EVTEvotec SE	6.484 € (11.45%)	630
1ENRSiemens Energy AG	64.00 € (10.92%)	22.42k
1UNHUnitedhealth Group Inc	397.90 € (-23.83%)	380
WUBM26Ulisse BioMed SpA	0.11 € (-21.37%)	831
WHIK26Haiki Spa	0.0663 € (-20.88%)	63.49k
FDAFidia	0.0047 € (-14.55%)	37.66M
SFTSoftlab SPA	0.524 € (-10.88%)	4.11k
TITTelecom Italia SpA	0.3213 € (0.09%)	197.12M
ISPIntesa Sanpaolo Spa	4.358 € (-0.88%)	52.8M
FDAFidia	0.0047 € (-14.55%)	37.66M
SPMSaipem Spa	1.8655 € (2.33%)	31.17M
ENELEnel Spa	7.369 € (1.04%)	25.07M

Símbolo

Precio

Vol.

TITTelecom Italia SpA

0.3213 €

(0.09%)

197.12M

ISPIntesa Sanpaolo Spa

4.358 €

(-0.88%)

52.8M

FDAFidia

0.0047 €

(-14.55%)

37.66M

SPMSaipem Spa

1.8655 €

(2.33%)

31.17M

ENELEnel Spa

7.369 €

(1.04%)

25.07M

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

Recordati SpA (REC)

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Acerca de Recordati SpA

REC Últimas noticias

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

REC - Preguntas Frecuentes

Movimientos

Discusión

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación

Tendencias Ahora

Listas Principales

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

Recordati SpA (REC) Cotización

Recordati SpA (REC)

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Acerca de Recordati SpA

REC Últimas noticias

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

REC - Preguntas Frecuentes

Movimientos

Discusión

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación

Quitar anuncios